CCR5 and neoplasm: Evidence suggesting CCR5 inhibition may augment immune checkpoint inhibitors or cellular immunotherapy (ICI) responses includes, firstly, evidence that CCR5 contributes to tumor progression by facilitating the recruitment of myeloid-derived suppressor cells and regulatory T cells to induce an immune-suppressive tumor microenvironment [141].